AstraZeneca's coronavirus vaccine is looking especially promising for the elderly

Andrew Cummings
October 27, 2020

Another potential coronavirus vaccine is moving along, with especially good news for the elderly.

"After the first and second phases with demonstrable safety profile and immunogenicity, a large-scale efficacy trial involving thousands of volunteers is being planned now", Dr E Venkata Rao, Principal Investigator in the Covaxin human trial and Professor in the department of Community Medicine at IMS and SUM Hospital, said on Sunday.

An experimental COVID-19 vaccine being developed in the United Kingdom produces an immune response in both younger and older adults, British drug maker AstraZeneca said, raising hopes in the fight against the coronavirus pandemic. Meanwhile, the British firm AstraZeneca has resumed the USA trial of the vaccine after approval by regulators-it was halted in September after a participant reported illness after getting the shot.


Scientists around the world are racing to develop a vaccine against Covid-19, which has killed over 1.1 million people. Asked if some people could receive a vaccine this year he replied: "I don't rule that out but that is not my central expectation".

Researchers looked whether the vaccine accurately follows the genetic instructions programmed into it by the Oxford team, providing clarity on how it provokes an immune response.

According to early trial results published in the medical journal The Lancet in July, the AZD1222 vaccine generated "robust immune responses" in a group of healthy adults aged between 18 and 55, without any serious side effects. It did not name the publication.


The two companies also announced that they had been greenlighted to resume their late-stage clinical trial into the vaccine. In addition, he also said that billions of vaccine doses are already being produced at factories across the world.

More than 200 vaccine candidates are now in development globally.

The candidate drug is now undergoing a much larger Phase III trial across several countries to try and establish how well it protects against coronavirus in a real-world setting.


Other reports by iNewsToday

FOLLOW OUR NEWSPAPER